This clinical trial is focused on studying the effectiveness and safety of a treatment for atopic dermatitis, a skin condition that causes red, itchy, and inflamed skin. The study involves participants aged 12 years and older who have moderate-to-severe forms of this condition. The treatment being tested is called amlitelimab, which is administered as a subcutaneous injection, meaning it is injected under the skin. Amlitelimab is a type of medication known as a monoclonal antibody, which is designed to target specific proteins in the body that may contribute to inflammation. The study will compare the effects of amlitelimab to a placebo to determine its effectiveness.

The purpose of the study is to evaluate how well amlitelimab works in reducing the symptoms of atopic dermatitis and to assess its safety. Participants will receive the treatment over a period of 24 weeks. During this time, they will have regular check-ups to monitor their skin condition and overall health. The study aims to see if amlitelimab can help clear the skin or significantly reduce the severity of the symptoms compared to those who receive a placebo.

In addition to amlitelimab, the study will also involve the use of other topical treatments like tacrolimus and pimecrolimus, which are applied directly to the skin. These treatments are commonly used to manage atopic dermatitis by reducing inflammation and itching. The study will help determine the best approach to treating moderate-to-severe atopic dermatitis and provide valuable information on the potential benefits of amlitelimab for patients with this condition.